Aura Biosciences (AURA) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aura Biosciences (AURA) has outperformed Prime Medicine (PRME) over the past year, gaining 12.2% versus a loss of 33.6%. Prime Medicine is the larger company by market cap ($707.4 million vs $669.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | PRME |
|---|---|---|
| Share price | $6.46 | $3.90 |
| Market cap | $669.93M | $707.37M |
| 1-day change | +4.70% | +11.43% |
| YTD return | +18.53% | +12.39% |
| 1-year return | +12.15% | -33.56% |
| EPS (TTM) | $-1.83 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $6.65 |
| 52-week low | $4.73 | $2.67 |
| Distance from 52-week high | -32.25% | -41.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +156.97% | +82.31% |
| Average volume | 748.04K | 3.19M |
| Shares outstanding | 103.70M | 181.38M |
| Employees | 113 | 146 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AURA has outperformed PRME by 45.7 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Healthcare · Biotechnology · 113 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Healthcare · Biotechnology · 146 employees
AURA vs PRME FAQ
Which is bigger, Aura Biosciences or Prime Medicine?
Prime Medicine (PRME) is larger, with a market capitalization of $707.37M compared with $669.93M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or PRME?
AURA returned +12.15% over the past 12 months, compared with -33.56% for PRME (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.